Seeking Alpha

Biogen (BIIB) -0.8% following its Q1 miss, which was due to weaker-than-expected sales of its...

Biogen (BIIB) -0.8% following its Q1 miss, which was due to weaker-than-expected sales of its Avonex multiple sclerosis drug. Still, net profit edged up 3% to $302.7M. Biogen upgraded its 2012 outlook, and it now expects adjusted EPS of over $6.15 and revenue growth in the mid-single digits.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|